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Abstract
Novel 2-arylthiazolidin-4-one derivatives (8a-q and 11) have been synthesized in good-to-excellent yields (70-96%)
by one-pot three-component condensation-cyclization reaction of aromatic or aliphatic primary amines, aromatic
aldehydes, and thioglycolic acid in polypropylene glycol at 110°C temperature. The in vitro antimicrobial activity of
the synthesized 2-arylthiazolidin-4-ones was investigated against a panel of six pathogenic fungal strains, a Gram-
positive and three Gram-negative bacteria. Results revealed that the compounds (8a-d) bearing 3-(4-(1H-
imidazolylmethyl)phenyl)-substituent displayed significant antibacterial efficacy specifically against Klebsiella
pneumoniae (minimum inhibitory concentration 12.5 μg/mL). In addition, some of the synthesized compounds
have also shown antimicotic activity against Sporothrix schenckii, Trichophyton mentagrophytes, and Aspergillus
fumigatus at the concentration of 50 μg/mL.
Graphical abstract: A series of novel 2-arylthiazolidin-4-one analogues was prepared and assessed for their in vitro
antimicrobial efficacy. Some of the synthesized compounds displayed significant antibacterial efficacy against
Klebsiella pneumoniae and selective antimycotic activity against Trichophyton mentagrophytes.
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Introduction
The increasing cases of microbial resistance pose a major
concern to the scientific community and have become a
threat for human life worldwide. Moreover, invasive
microbial infections caused by multi-drug-resistant Gram-
positive bacteria and microbes are difficult to diagnose
and treat [1]. They are the major cause of morbidity and
mortality especially in immunosuppressed and hospital-
a c q u i r e dp a t i e n t s[ 2 ] .T oo v e r c o m et h e s ep r o b l e m s ,t h e
development of new and safe antimicrobial agents with
better effectiveness is urgently required. To this end, one
of the best ways to design new antimicrobial agents is to
generate hybrid molecules by combining two bioactive
heterocyclic moieties in a single molecular scaffold.
Among pharmacologically important heterocyclic com-
pounds, 4-thiazolidinone derivatives have been known to
possess a wide range of biological properties such as
anticonvulsant [3], anti-HIV [4], antifungal [5], antibac-
terial agents [6], and COX-1 inhibitors [7]. In addition,
the five- and six-membered heterocycles, such as imida-
zole, triazole, and morpholine are of great interest due to
their presence in many pharmaceutical agents [8-10].
Owing to the biological significance of these two classes
of compounds and in continuation of our ongoing study
on antimicrobial agents [11], we planned to synthesize a
combined molecular framework that involves these two
different chromophores. Thus, a series of 2-arylthiazoli-
din-4-ones bearing imidazole, triazole, or morpholine
moiety has been synthesized using one-pot three-compo-
nent methodology [12] to investigate their antibacterial
and antimycotic efficacy.
Results and discussion
Chemistry
The starting materials, 4-((1H-imidazol-1-yl)methyl)ani-
line (4a), 4-((1H-1,2,4-triazol-1-yl)methyl)aniline (4b),
and 4-(morpholinomethyl)aniline (4c) were prepared
from 4-nitro-toluene in three steps. The bromination of
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provided the original work is properly cited.4-nitrotoluene (1)w i t hN-bromosuccinimide in the pre-
sence of catalytic amount of benzoyl peroxide was
accomplished in carbon tetrachloride at reflux tempera-
ture. The resulting product, p-nitrobenzyl bromide (2),
was then coupled with imidazole, 1,2,4-triazole, or mor-
pholine according to the reported procedure [13], in the
presence of DBU as a base in THF at ambient tempera-
ture to afford compounds (3a-c) which on subsequent
reduction with SnCl2 in hydrochloric acid at 50-60°C
yielded products (4a-c; Scheme Scheme 1). The physical
and spectral data of compounds (4a-c) are in agreement
with the reported data [14-16]. 4-Morpholinobenzena-
mine (5) and 3-morpholinopropan-1-amine (9) were pur-
chased from Sigma-Aldrich and used without further
purification. The synthetic routes to the target com-
pounds are outlined in Schemes Scheme 2 and 3. For the
synthesis of 2-arylthiazolidin-4-ones (8a-q and 11), the
condensation-cyclization reactions of various amines
(4a-c, 5, and 9), aromatic aldehydes, and thioglycolic acid
were performed at 110°C using polypropylene glycol
(PPG) as a solvent medium. Initially, we attempted the
synthesis of 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-2-
phenylthiazolidin-4-one (8a) by reacting 4-((1H-imida-
zol-1-yl)methyl)aniline (4a) with benzaldehyde and thio-
glycolic acid at 110°C in polyethylene glycol (PEG), as
many organic transformations and multi-component
reactions are reported in PEG, but surprisingly, no pro-
duct formation was observed even after 24 h of the reac-
tion. However, the reaction proceeds well in PPG under
same reaction conditions and afforded the proffered pro-
duct 8a in 83% yield. The success of the reaction in PPG
is possibly due to its immiscibility with water, which
helps in the removal of a water molecule from the reac-
tion mixture during the formation of 4-thiazolidinone
ring. In addition, PPG is an eco-friendly solvent and asso-
ciated with many advantages, such as low cost, less toxi-
city, efficient recyclability, easy work-up, and miscibility
with a wide range of organic solvents.
The newly synthesized compounds were characterized
by IR,
1HN M R ,
13C NMR, ESI-MS, and elemental ana-
lysis. The formation of 3-(4-((1H-imidazol-1-yl)methyl)
phenyl)-2-phenylthiazolidin-4-one (8a)w a sf i r s ti n d i -
cated by IR. In IR spectrum, the compound 8a exhibited
a sharp band at 1686 cm
-1 because of CO stretching.
The structure of compound 8a was confirmed by NMR
spectroscopy. In
1H NMR, the appearance of two doub-
lets at δ 3.99 and 3.86 ppm due to geminal coupling
between two hydrogens of S-CH2-CO and a sharp sing-
let at δ 6.08 ppm corresponding to N-CH-S indicated
the presence of thiazolidinone ring. Similarly, three car-
bon signals at δ 33.30, 65.24, and 171.05 ppm in the
13C
NMR of 8a were assigned to S-CH2,N - CH-S, and CO
groups, respectively. The mass spectral analysis pro-
duced further evidence for the formation of 8a by
showing [M]
+ ion peak at m/z 335 for the molecular
formula, C19H17N3OS. The general synthetic method
and characterization data of compounds (8a-q and 11)
are described in the “Experimental section.”
Biological evaluation
The in vitro antibacterial activities of compounds (8a-q
and 11) and standard drugs (gentamycin and ampicillin)
were carried out against a Gram-positive bacterial strain
viz. Staphylococcus aureus (Sa) and three Gram-negative
bacteria viz. Escherichia coli (Ec), Klebsiella pneumoniae
(Kp) and Pseudomonas aeruginosa (Pa). The results of pre-
liminary in vitro antibacterial testing are shown in Table 1.
Out of 18 newly synthesized compounds, only 7 com-
pounds (8a-f and q) were found to be active against the
tested bacterial strains. 4-Thiazolidinones (8a-f) bearing
4-(1H-imidazolylmethyl)phenyl)-substituent at position 3
were found significantly active (minimum inhibitory con-
centration–MIC 12.5-50 μg/mL) against Gram-negative
strain Kp. In addition, compounds (8a-c) have also shown
moderate activity against Sa. In contrast, thiazolidinone 8q
with 3-(4-morpholinophenyl)-substituent exhibited activity
(50 μg/mL) specifically against a Gram-negative bacterial
strain Ec, which was found to be comparable with the
standard drug ampicillin. Surprisingly, 4-thiazolidinone
derivatives containing 4-(1,2,4-triazolylmethyl)phenyl- and
4-(morpholinomethyl)phenyl-functionalities at position 3
were found inactive against all the tested bacterial strains.
These results imply that the nature of substituent at
Scheme 1 Synthetic routes to 4-substituted phenylamines
(4a-c). Reagents and conditions: (a) NBS, benzoyl peroxide, CCl4,
reflux, 4-5 h; (b) DBU, imidazole or 1,2,4-triazole or morpholine, THF,
room temperature, 20-24 h; (c) SnCl2 2H2O, conc. HCl, 50-60°C, 5-6 h.
Scheme 2 Synthetic routes to 2-arylthiazolidin-4-one
derivatives (8a-q).
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terial activity.
Furthermore, the in vitro antifungal activity of com-
pounds (8a-q and 11) was investigated along with stan-
dard drugs Ketoconazole and Fluconazole against a
panel of six fungal strains, viz., Candida albicans (Ca),
Cryptococcus neoformans (Cn), Sporothrix schenckii (Ss),
Trichophyton mentagrophytes (Tm), Aspergillus fumiga-
tus (Af), and Candida parapsilosis (Cp) and the results
a r ep r e s e n t e di nT a b l e2 .A l t h o u g h ,n o n eo ft h ec o m -
pounds showed better efficacy than the standard drugs
Ketoconazole and Fluconazole against the tested fungi,
12 of the title compounds (8a, 8g-q) were found to be
equipotent against Tm with MIC value of 50 μg/mL.
The antifungal activity profile of these molecules seems
to be dependent mainly on the substitution at position 3
of the thiazolidinone ring. Compounds 8g-i containing
4-(1,2,4-triazolylmethyl)phenyl-moiety were found to be
equipotent (MIC 50 μg/mL) against two fungal patho-
gens, Ss and Tm, whereas the compounds 8a with
4-(1H-imidazolylmethyl)phenyl)-substituent and 8k-q
with 4-(morpholinomethyl)phenyl- or 4-morpholinophe-
nyl-group displayed selective efficacy (MIC 50 μg/mL)
against Tm. The remaining compounds (8b-f) having 4-
(1H-imidazolylmethyl)phenyl)-group at position 3 of the
thiazolidinone ring were found inactive against the
screened fungi. Similarly, 3-(3-morpholinopropyl)-2-(4-
(trifluoromethyl)phenyl)thiazolidin-4-one (11)d i dn o t
show any activity against the tested microbial strains.
These results indicate that the thiazolidinone ring does
not have any influence on the activity profile of these
molecules. However, the heteroaromatic moiety present
at position 3 in the thiazolidinone ring seems to be
responsible for the antimicrobial activity.
Conclusions
In summary, various 2-arylthiazolidin-4-ones (8a-q)a n d
3-(3-morpholinopropyl)-2-(4-(trifluoromethyl)phenyl)
thiazolidin-4-one (11) have been synthesized via one-pot
three-component methodology using PPG as a solvent
medium and screened for their in vitro antimicrobial
efficacy. It was observed that, instead of thiazolidinone
ring, the heteroaromatic moiety at position 3 contributes
to the antimicrobial activity. Compounds bearing
Scheme 3 Synthesis of 3-(3-morpholinopropyl)-2-(4-
(trifluoromethyl)phenyl)thiazolidin-4-one (11).
Table 1 In vitro antibacterial activities of compounds
8a-q and 11
Compound RR 1 R2 R3 R4 R5 MIC (μg/mL)
Ec Pa Sa Kp
8a H H H H H > 50 > 50 50 12.5
8b HH C F 3 H H > 50 > 50 50 12.5
8c H H Br H H > 50 > 50 50 12.5
8d H H Cl H H > 50 > 50 > 50 12.5
8e HH C H 3 H H > 50 > 50 > 50 25
8f H H F H H > 50 > 50 > 50 50
8g CF3 H H H H > 50 > 50 > 50 > 50
8h F F F F F > 50 > 50 > 50 > 50
8i H H Br H H > 50 > 50 > 50 > 50
8j H H F H H > 50 > 50 > 50 > 50
8k H H Br H H > 50 > 50 > 50 > 50
8l HH C F 3 H H > 50 > 50 > 50 > 50
8m H H Br H H > 50 > 50 > 50 > 50
8n H H Cl H H > 50 > 50 > 50 > 50
8o H Br H H H > 50 > 50 > 50 > 50
8p H Cl H H H > 50 > 50 > 50 > 50
8q H F H H H 50 > 50 > 50 > 50
11 - - - - - - > 50 > 50 > 50 > 50
Gentamycin - - - - - - 0.78 0.78 0.39 0.78
Ampicillin - - - - - - 50 50 0.19 0.39
Ec, E. coli (ATCC 9637); Pa, P. aeruginosa (ATCC BAA-427); Sa, S. aureus (ATCC
25923); Kp, K. pneumonia (ATCC 27736).
Table 2 In vitro antifungal activities of compounds 8a-q
and 11
Compound MIC (μg/mL)
Ca Cn Ss Tm Af Cp
8a > 50 > 50 > 50 50 > 50 > 50
8b > 50 > 50 > 50 > 50 > 50 > 50
8c > 50 > 50 > 50 > 50 > 50 > 50
8d > 50 > 50 > 50 > 50 > 50 > 50
8e > 50 > 50 > 50 > 50 > 50 > 50
8f > 50 > 50 > 50 > 50 > 50 > 50
8g > 50 > 50 50 50 > 50 > 50
8h > 50 > 50 50 50 > 50 > 50
8i > 50 > 50 50 50 > 50 > 50
8j > 5 0> 5 0> 5 05 0 5 0 > 5 0
8k > 50 > 50 > 50 50 > 50 > 50
8l > 50 > 50 > 50 50 > 50 > 50
8m > 50 > 50 > 50 50 > 50 > 50
8n > 50 > 50 > 50 50 > 50 > 50
8o > 50 > 50 > 50 50 > 50 > 50
8p > 50 > 50 > 50 50 > 50 > 50
8q > 50 > 50 > 50 50 > 50 > 50
11 > 50 > 50 > 50 > 50 > 50 > 50
Ketoconazole 0.002 0.001 0.031 4.0 2.0 0.031
Fluconazole 0.5 1.0 2.0 1.0 2.0 1.0
Ca, C. albicans; Cn, C. neoformans;S s ,S. schenckii; Tm, T. mentagrophytes; Af,
A. fumigatus; Cp, C. parapsilosis (ATCC-22019).
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zolidinone ring showed significant antibacterial efficacy
(MIC 12.5-50 μg/mL) against Gram-negative strain Kp,
while compounds with the corresponding 1,2,4-triazole
and morpholine substituents displayed comparable anti-
mycotic activity (MIC 50 μg/mL) against Tm. Further-
more, these results may be useful for the designing of
potent new antimicrobial agents.
Experimental
Chemistry
All the chemicals were purchased from Sigma-Aldrich and
used without any further purification. Thin-layer chroma-
tography was performed on precoated Merck silica gel
60 F254 plates, and spots were developed under UV light
(254 nm) or in iodine chamber. All the compounds were
purified by column chromatography using silica gel (60-
120 mesh). The
1H NMR spectra were recorded on Bruker
300 or Jeol 400 MHz spectrometer. The IR spectra were
obtained on a Perkin Elmer IR spectrometer, and peaks
are given in reciprocal centimeter (cm
-1). Mass spectra
were recorded on Waters Micromass LCT ESI-MS spec-
trometer in positive ionization mode. Elemental analyses
were determined on Elementar Analysensysteme GmbH
VarioEL V3.00, and CHNS values were found within ± 0.4
of theoretical values for all the new compounds. The melt-
ing points were obtained by Perkin Elmer differential scan-
ning calorimetry.
General procedure for the synthesis of 8a-q and 11
A mixture of amine (1 mmol), aldehyde (2 mmol), and
thioglycolic acid (3 mmol) in PPG ~2000 (2 mL) was
heated at 110°C for 4-11 h. After completion of the reac-
tion as indicated by TLC, the reaction mixture was diluted
with hexane, and the precipitated product was filtered. In
the case of oily products, the hexane layer was decanted,
and sticky material was dissolved in ethyl acetate (20 mL).
The solution was washed well with saturated NaHCO3
solution (15 mL × 3 times) followed by water (15 mL ×
3 times). The organic layer was dried over anhydrous
sodium sulfate and evaporated under reduced pressure to
afford the crude compound. The product was purified by
column chromatography on silica gel using 2-4% MeOH
in benzene as eluent. In addition, the hexane layer was
evaporated under reduced pressure to recover PPG which
can be recycled.
3-(4-((1H-imidazol-1-yl)methyl)phenyl)-2-phenylthiazolidin-4-
one (8a)
Brown gummy oil; yield 83%. IR (CHCl3) ν: 1686 (C = O),
1513, 1425, 1356, 1273, 1217 1137, 1017, 957, 899, 863,
821, 755, 679 cm
-1;
1H NMR (300 MHz, CDCl3) δ:7 . 5 3( s ,
1 H, imidazole H), 7.28-7.26 (m, 4 H, ArH), 7.17 (d, J =8 . 7
Hz, 2 H, ArH), 7.06 (s, 1 H, imidazole H), 7.03 (d, J =8 . 4
Hz, 3 H, ArH), 6.83 (s, 1 H, imidazole H), 6.08 (s, 1 H,
CH), 5.03 (s, 2 H, CH2-Ph) 3.99 (d, J =1 5 . 9H z ,1H ,C H 2),
3.86 (d, J =1 5 . 9H z ,1H ,C H 2) ppm;
13C NMR (100 MHz,
CDCl3) δ: 171.05, 139.09, 137.20, 134.61, 129.29, 128.91,
128.86, 127.69, 126.71, 125.75, 119.25, 65.24, 50.02, 33.30
ppm; MS (ESI): m/z 335 [M]
+.
3-(4-((1 H-imidazol-1-yl)methyl)phenyl)-2-(4-(trifluoromethyl)
phenyl)thiazolidin-4-one (8b)
Yellow solid; m.p. 166°C; yield 86%. IR (CHCl3) ν:1 6 8 3
(C = O), 1515, 1380, 1326, 1232, 1166, 1123, 1067, 1017,
853, 753, 663 cm
-1;
1H NMR (400 MHz, CDCl3) δ:7 . 5 6( d ,
J = 8.2 Hz, 2 H, ArH), 7.50 (s, 1 H, imidazole H), 7.40 (d,
J = 8.2 Hz, 2 H, ArH), 7.18 (dd, J1 =7 . 7H z ,J2 = 1.83 Hz,
2 H, ArH), 7.07 (s, 1 H, imidazole H), 7.05 (d, J = 8.7 Hz,
2H ,A r H ) ,6 . 8 3( s ,1H ,i m i d a z o l eH ) ,6 . 1 4( s ,1H ,C H ) ,
5.04 (s, 2 H, CH2Ph), 3.98 (dd, J1 = 16.0 Hz, J2 = 1.3 Hz, 1
H, CH2), 3.87 (d, J = 15.5 Hz, 1 H, CH2) ppm;
13CN M R
(100 MHz, CDCl3) δ: 170.91, 143.30, 137.04, 135.03,
129.52, 127.85, 127.06, 126.01, 125.97, 125.54, 64.39, 49.99,
33.21 ppm; MS (ESI): m/z 404 [M + H]
+; Anal. calcd for
C20H16F3N3OS.1.1 H2O: C, 56.76; H, 4.33; N, 9.93; S, 7.58.
Found: C, 56.63; H, 4.08; N, 9.55; S, 7.59.
3-(4-((1 H-imidazol-1-yl)methyl)phenyl)-2-(4-bromophenyl)
thiazolidin-4-one (8c)
Yellow solid; m.p. 180°C; yield 82%. IR (CHCl3) ν:1 6 8 3
(C = O), 1610, 1515, 1488, 1374, 1290, 1231, 1177, 1107,
1073, 1030, 1010, 906, 820, 752, 663 cm
-1;
1HN M R( 4 0 0
MHz, CDCl3) δ: 7.49 (s, 1 H, imidazole H), 7.42 (dd, J1 =
6.4 Hz, J2 = 1.8 Hz, 2 H, ArH), 7.16 (d, J = 1.3 Hz, 2 H,
ArH), 7.14 (d, J = 1.3 Hz, 2 H, ArH), 7.07 (s, 1 H, imida-
zole H), 7.04 (d, J = 8.7 Hz, 2 H, ArH), 6.84 (s, 1 H, imida-
zole H), 6.05 (s, 1 H, CH), 5.05 (s, 2 H, CH2Ph), 3.96 (dd,
J1 = 16.0 Hz, J2 = 1.3 Hz, 1 H, CH2), 3.86 (d, J = 16.0 Hz,
1H ,C H 2) ppm;
13C NMR (100 MHz, CDCl3) δ: 171.01,
138.36, 137.27, 135.23, 132.30, 132.20, 128.71, 128.62,
127.91, 125.98, 125.89, 123.09, 64.83, 50.12, 33.45 ppm;
MS (ESI): m/z 413 [M]
+;A n a l .c a l c df o rC 19H16BrN3OS
0.2C6H6 0.8H2O: C, 54.60; H, 4.26; N, 9.46; S, 7.22. Found:
C, 54.66; H, 4.12; N, 9.05; S, 7.59.
3-(4-((1 H-imidazol-1-yl)methyl)phenyl)-2-(4-chlorophenyl)
thiazolidin-4-one (8d)
Yellow solid; m.p.160°C; yield 78%. IR (CHCl3) ν: 1686 (C
= O), 1508, 1376, 1290, 1231, 1088, 1030, 1014, 906, 839,
749, 691, 662, 615 cm
-1;
1H NMR (400 MHz, CDCl3) δ:
7.51 (s, 1 H, imidazole H), 7.28-7.27 (m, 1 H, ArH),7.24
(dd, J1 = 9.1 Hz, J2 = 1.8 Hz, 2 H, ArH), 7.22-7.20 (m, 1 H,
ArH), 7.15 (dd, J1 = 6.6 Hz, J2 = 2.2 Hz, 2 H, ArH), 7.07 (s,
1 H, imidazole H), 7.03 (d, J = 8.7 Hz, 2 H, ArH), 6.84 (s,
1 H, imidazole H), 6.07 (s, 1 H, CH), 5.04 (s, 2 H, CH2Ph),
3.96 (dd, J1 = 16.0 Hz, J2 = 1.3 Hz, 1 H, CH2), 3.86 (dd, J1
=1 5 . 5H z ,J2 =0 . 9H z ,1H ,C H 2) ppm;
13CN M R( 1 0 0
MHz, CDCl3) δ: 170.90, 137.63, 137.32, 137.13, 135.02,
134.77, 129.63, 129.16, 128.27, 127.78, 125.83, 119.30,
64.58, 50.02, 33.33 ppm; MS (ESI): m/z 369 [M]
+;A n a l .
calcd for C19H16ClN3OS 0.1 H2O: C, 61.40; H, 4.39; N,
11.31; S, 8.63. Found: C, 61.66; H, 4.12; N, 11.05; S, 8.48.
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4-one (8e)
Brown gummy matter; yield 87%. IR (CHCl3) ν:1 6 8 4( C=
O), 1505, 1372, 1107, 1076, 906, 821, 751, 663 cm
-1;
1H
NMR (400 MHz, CDCl3) δ:7 . 4 9( s ,1H ,i m i d a z o l eH ) ,
7.17 (d, J = 6.4 Hz, 2 H, ArH),7.15 (d, J =5 . 5H z ,2H ,
ArH), 7.09 (d, J = 8.2 Hz, 2 H, ArH), 7.05 (d, J =9 . 1H z ,
2 H, ArH), 7.02 (s, 1 H, imidazole H), 6.83 (s, 1 H, imida-
z o l eH ) ,6 . 0 5( s ,1H ,C H ) ,5 . 0 3( s ,2H ,C H 2Ph), 3.97 (d,
J =1 5 . 5H z ,1H ,C H 2), 3.84 (d, J =1 5 . 5H z ,1H ,C H 2),
2.29 (s, 3H, CH3) ppm; MS (ESI): m/z 350 [M + H]
+.
3-(4-((1 H-imidazol-1-yl)methyl)phenyl)-2-(4-fluorophenyl)
thiazolidin-4-one (8f)
Yellow solid; m.p. 70°C; yield 74%. IR (CHCl3) ν:1 6 8 6( C=
O), 1604, 1510, 1378, 1280, 1227, 1157, 1107, 1076, 1030,
906, 847, 823, 788, 753, 692, 663 cm
-1;
1HN M R
(400 MHz, CDCl3) δ: 7.48 (s, 1 H, imidazole H), 7.28-7.25
(m, 2 H, ArH),7.14 (dd, J1 =6 . 6H z ,J2 = 1.8 Hz, 2 H,
ArH), 7.07 (s, 1 H, imidazole H), 7.03 (d, J = 8.2 Hz, 2 H,
ArH), 6.98 (dd, J1 = 6.4 Hz, J2 = 1.8 Hz, 2 H, ArH), 6.83 (t,
J = 0.92 Hz, 1 H, imidazole H), 6.08 (s, 1 H, CH), 5.04 (s,
2H ,C H 2Ph), 3.96 (dd, J1 = 15.8 Hz, J2 = 1.8 Hz, 1 H,
CH2), 3.87 (d, J = 16.0 Hz, 1 H, CH2) ppm; MS (ESI): m/z
354 [M + H]
+; Anal. calcd for C19H16FN3OS 0.4H2O: C,
63.28; H, 4.70; N, 11.65; S, 8.89. Found: C, 63.46; H, 4.58;
N, 11.50; S, 8.66.
3-(4-((1 H-1,2,4-triazol-1-yl)methyl)phenyl)-2-(2-
(trifluoromethyl)phenyl)thiazolidin-4-one (8g)
Yellow solid; m.p. 176°C; yield 88%. IR (CHCl3) ν:1 6 9 1( C
= O), 1509, 1341, 1314, 1273, 1217, 1166, 1117, 1060,
1039, 1017, 958, 768, 724, 679, 651 cm
-1;
1H NMR (300
MHz, CDCl3) δ: 8.01 (s, 1 H, triazole H), 7.94 (s, 1 H, tria-
zole H), 7.61 (d, J = 7.8 Hz, 1 H, ArH), 7.54 (m, 2 H, ArH),
7.40-7.36 (m, 1 H, ArH), 7.30 (d, J = 8.4 Hz, 2 H, ArH),
7.17 (d, J = 8.4 Hz, 2 H, ArH), 6.56 (s, 1 H, CH), 5.26 (s,
2H ,C H 2-Ph), 3.99 (d, J = 15.9 Hz, 1 H, CH2), 3.86 (d, J =
15.9 Hz, 1 H, CH2)p p m ;M S( E S I ) :m/z 405 [M + H]
+;
Anal. calcd for C19H15F3N4OS 0.3H2O: C, 55.68; H, 3.84;
N, 13.67; S, 7.82. Found: C, 55.46; H, 3.62; N, 13.55; S,
7.62.
3-(4-((1 H-1,2,4-triazol-1-yl)methyl)phenyl)-2-
(pentafluorophenyl)thiazolidin-4-one (8h)
White solid; m.p. 120°C; yield 70%. IR (CHCl3) ν:1 6 9 2( C
= O), 1560, 1541, 1506, 1420, 1389, 1339, 1273, 1223,
1138, 1116, 1017, 994, 962, 760, 732, 679, 621 cm
-1;
1H
NMR (300 MHz, CDCl3) δ: 8.08 (s, 1 H, triazole H), 7.97
(s, 1 H, triazole H), 7.29 (d, J = 8.4 Hz, 2 H, ArH), 7.23
(d, J = 8.4 Hz, 2 H, ArH), 6.55 (s, 1 H, CH), 5.31 (s, 2 H,
CH2-Ph), 4.09 (d, J =1 5 . 6H z ,1H ,C H 2), 3.87 (d, J =
1 5 . 6H z ,1H ,C H 2) ppm; MS (ESI): m/z 427 [M + H]
+;
Anal. calcd for C18H11F5N4OS.: C, 50.71; H, 2.60; N,
13.14; S, 7.52. Found: C, 50.61; H, 2.52; N, 13.45; S, 7.45.
3-(4-((1 H-1,2,4-triazol-1-yl)methyl)phenyl)-2-(4-
bromophenyl)thiazolidin-4-one (8i)
Yellow solid; m.p. 178°C; Yield 76%. IR (CHCl3) ν:1 6 8 7
(C = O), 1514, 1489, 1376, 1272, 1217, 1137, 1072, 1011,
958, 842, 751, 679 cm
-1;
1H NMR (300 MHz, CDCl3) δ:
8.04 (s, 1 H, triazole H), 7.95 (s, 1 H, triazole H), 7.42 (d,
J = 7.8 Hz, 2 H, ArH), 7.17 (m, 6H, ArH), 6.06 (s, 1 H,
CH), 5.27 (s, 2 H, CH2-Ph), 3.96 (d, J =1 5 . 0H z ,1H ,
CH2), 3.85 (d, J = 15.9 Hz, 1 H, CH2) ppm; MS (ESI): m/z
415 [M + H]
+; Anal. calcd for C18H15BrN4OS 0.35H2O: C,
51.28; H, 3.75; N, 13.29; S, 7.61. Found: C, 51.36; H, 3.96;
N, 12.98; S, 7.69.
3-(4-((1 H-1,2,4-triazol-1-yl)methyl)phenyl)-2-(4-fluorophenyl)
thiazolidin-4-one (8j)
Yellow solid; m.p. 130°C; yield 78%. IR (CHCl3) ν:1 6 8 6
(C = O), 1605, 1510, 1376, 1273, 1225, 1158, 1138, 1016,
958, 848, 789, 755, 679 cm
-1;
1H NMR (300 MHz, CDCl3)
δ: 8.02 (s, 1 H, triazole H), 7.95 (s, 1 H, triazole H), 7.27-
7.24 (m, 2 H, ArH), 7.16 (m, 4 H, ArH), 6.97 (t, J = 8.4 Hz,
2 H, ArH), 6.09 (s, 1 H, CH), 5.26 (s, 2 H, CH2-Ph), 3.96
(d, J = 15.9 Hz, 1 H, CH2), 3.86 (d, J = 15.9 Hz, 1 H, CH2)
ppm; MS (ESI): m/z 355 [M + H]
+; Anal. calcd for
C18H15FN4OS 0.15 H2O: C, 60.54; H, 4.32; N, 15.69; S,
8.98. Found: C, 60.78; H, 4.02; N, 15.45; S, 8.85.
2-(4-Bromophenyl)-3-(4-(morpholinomethyl)phenyl)
thiazolidin-4-one (8k)
Gummy brown solid; yield 82%. IR (CHCl3) ν:1 6 9 3( C=
O), 1679, 1609, 1512, 1487, 1454, 1379, 1290, 1264, 1217,
1177, 1115, 1071, 1035, 1008, 914, 865, 838, 797, 754, 664,
644, 624 cm
-1;
1H NMR (400 MHz, CDCl3) δ:7 . 4 1( d d ,
J1 =6 . 6H z ,J2 = 1.6 Hz, 2 H, ArH), 7.25 (d, J =8 . 4H z ,
2 H, ArH), 7.16 (dd, J1 =6 . 7H z ,J2 = 1.6 Hz, 2 H, ArH),
7.09 (d, J = 8.2 Hz, 2 H, ArH), 6.04 (s, 1 H, CH), 3.96 (dd,
J1 = 15.8 Hz, J2 = 1.3 Hz, 1 H, CH2), 3.86 (d, J = 15.8 Hz,
1H ,C H 2), 3.67 (t, J = 4.5 Hz, 4 H, morpholine H), 3.40 (s,
2H ,C H 2-Ph), 2.38 (t, J = 4.3 Hz, 4 H, morpholine H)
ppm;
13C NMR (100 MHz, CDCl3) δ: 170.83, 138.52,
136.71, 136.06, 131.97, 129.76, 128.54, 125.28, 122.75,
66.76, 64.82, 62.53, 53.43, 33.30 ppm; MS (ESI): m/z 433
[M + H]
+.
3-(4-Morpholinophenyl)-2-(4-(trifluoromethyl)phenyl)
thiazolidin-4-one (8l)
Dark brown gummy solid; m.p. 110°C; yield 94%. IR
(CHCl3) ν: 1682 (C = O), 1609, 1516, 1450, 1421, 1379,
1325, 1263, 1165, 1120, 1067, 1017, 930, 851, 825, 803,
752, 659 cm
-1;
1H NMR (400 MHz, CDCl3) δ: 7.55 (d, J =
8.2 Hz, 2 H, ArH), 7.41 (d, J = 8.2 Hz, 2 H, ArH), 7.02 (dd,
J1 = 6.8 Hz, J2 = 2.0 Hz, 2 H, ArH), 6.78 (dd, J1 = 6.8 Hz, J2
= 2.0 Hz, 2 H, ArH), 6.04 (s, 1 H, CH), 3.99 (dd, J1 = 15.8
Hz, J2 = 1.6 Hz, 1 H, CH2), 3.88 (d, J =1 5 . 8H z ,1H ,C H 2),
3.79 (t, J = 4.8 Hz, 4 H, morpholine H), 3.09 (t, J = 5.0 Hz,
4 H, morpholine H) ppm; MS (ESI): m/z 409 [M + H]
+.
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(8m)
Bright yellow solid; m.p. 144°C; yield 85%. IR (CHCl3) ν:
1683 (C = O), 1608, 1516, 1488, 1449, 1408, 1378, 1334,
1292, 1263, 1234, 1178, 1121, 1071, 1052, 1009, 930, 824,
798, 757, 665, 648 cm
-1;
1H NMR (400 MHz, CDCl3) δ:
7.41 (dd, J1 = 6.5 Hz, J2 = 1.8 Hz, 2 H, ArH), 7.17 (dd, J1 =
6.5 Hz, J2 = 1.8 Hz, 2 H, ArH), 6.98 (dd, J1 =6 . 8H z ,J2 =
2.0 Hz, 2 H, ArH), 6.78 (dd, J1 = 6.8 Hz, J2 = 2.0 Hz, 2 H,
ArH), 5.95 (d, J = 1.3 Hz, 1 H, CH), 3.96 (dd, J1 =1 5 . 8H z ,
J2 = 1.8 Hz, 1 H, CH2), 3.86 (d, J =1 5 . 5H z ,1H ,C H 2),
3.80 (t, J = 4.8 Hz, 4 H, morpholine H), 3.09 (t, J = 4.8 Hz,
4 H, morpholine H) ppm;
13C NMR (100 MHz, CDCl3) δ:
170.82, 149.99, 138.67, 131.86, 128.78, 128.62, 126.81,
122.70, 115.63, 66.61, 65.05, 48.60, 33.20 ppm; MS (ESI):
m/z 419 [M + H]
+. Anal. calcd for C19H19BrN2O2S
0.15C6H6: C, 55.45; H, 4.65; N, 6.50; S, 7.44. Found: C,
55.45; H, 4.45; N, 6.37; S, 7.39.
2-(4-Chlorophenyl)-3-(4-morpholinophenyl)thiazolidin-4-
one (8n)
Yellow solid; m.p. 132°C; Yield 78%. IR (CHCl3) ν:1 6 8 3
(C = O), 1607, 1515, 1491, 1449, 1378, 1334, 1262, 1234,
1177, 1120, 1088, 1051, 1013, 930, 825, 756, 653 cm
-1;
1H
NMR (400 MHz, CDCl3) δ: 7.27-7.22 (m, 4 H, ArH), 6.98
(dd, J1 = 6.8 Hz, J2 = 2.3 Hz, 2 H, ArH), 6.78 (dd, J1 =6 . 8
Hz, J2 = 2.0 Hz, 2 H, ArH), 5.96 (d, J = 1.6 Hz, 1 H, CH),
3.96 (dd, J1 = 15.7 Hz, J2 = 1.8 Hz, 1 H, CH2), 3.86 (d, J =
15.8 Hz, 1 H, CH2), 3.80 (t, J = 4.8 Hz, 4 H, morpholine
H), 3.09 (t, J = 3.4 Hz, 4 H, morpholine H) ppm;
13CN M R
(100 MHz, CDCl3) δ: 170.84, 150.02, 138.14, 134.52,
128.92, 128.65, 128.52, 126.86, 115.64, 66.62, 65.03, 48.63,
33.22 ppm; MS (ESI): m/z 375 [M + H]
+; Anal. calcd for
C19H19ClN2O2S 0.15C6H6: C, 61.82; H, 5.19; N, 7.25; S,
8.29. Found: C, 61.73; H, 5.45; N, 7.24; S, 8.32.
2-(3-Bromophenyl)-3-(4-morpholinophenyl)thiazolidin-4-
one (8o)
B r o w ns o l i d ;m . p .1 0 6 ° C ;y i e l d9 1 % .I R( C H C l 3) ν:1 6 8 5
(C = O), 1608, 1593, 1573, 1516, 1474, 1449, 1431, 1378,
1330, 1262, 1234, 1179, 1121, 1070, 1052, 930, 902, 826,
796, 756, 686, 666 cm
-1;
1H NMR (400 MHz, CDCl3) δ:
7.45-7.36 (m, 1 H, ArH), 7.36 (s, 1 H, ArH), 7.22-7.14 (m,
2 H, ArH), 7.01 (dd, J1 =6 . 7H z ,J2 = 2.0 Hz, 2 H, ArH),
6.79 (dd, J1 =6 . 8H z ,J2 = 2.3 Hz, 2 H, ArH), 5.92 (d, J =
1.6 Hz, 1 H, CH), 3.98 (dd, J1 = 15.7 Hz, J2 = 1.8 Hz, 1 H,
CH2), 3.86 (d, J = 15.8 Hz, 1 H, CH2), 3.80 (t, J =4 . 8H z ,
4 H, morpholine H), 3.10 (t, J = 5.0 Hz, 4 H, morpholine
H) ppm; MS (ESI): m/z 419 [M + H]
+; Anal. calcd for
C19H19BrN2O2S: C, 54.42; H, 4.57; N, 6.68; S, 7.65. Found:
C, 54.78; H, 4.33; N, 6.45; S, 7.85.
2-(3-Chlorophenyl)-3-(4-morpholinophenyl)thiazolidin-4-
one (8p)
Yellow solid; m.p. 122°C; yield 88%. IR (CHCl3) ν: 1686
(C = O), 1608, 1577, 1516, 1477, 1449, 1378, 1331,
1262, 1234, 1121, 1077, 1052, 930, 894, 860, 826, 798,
757, 685, 657, 615 cm
-1;
1H NMR (400 MHz, CDCl3) δ:
7.36-7.29 (m, 1 H, ArH), 7.23-7.22 (m, 2 H, ArH), 7.17-
7.16 (m, 1 H, ArH), 7.01 (dd, J1 =6 . 8H z ,J2 = 2.0 Hz, 2
H, ArH), 6.79 (dd, J1 =7 . 0H z ,J2 = 2.2 Hz, 2 H, ArH),
5.93 (d, J = 1.6 Hz, 1 H, CH), 3.98 (dd, J1 =1 5 . 8H z ,J2
= 1.8 Hz, 1 H, CH2), 3.86 (d, J =1 5 . 8H z ,1H ,C H 2),
3.80 (t, J = 4.8 Hz, 4 H, morpholine H), 3.09 (t, J =4 . 8
Hz, 4 H, morpholine H) ppm;
13C NMR (100 MHz,
CDCl3) δ: 170.85, 150.05, 141.94, 134.57, 130.03, 128.96,
128.68, 127.13, 126.79, 125.15, 115.69, 66.63, 65.01,
48.66, 33.14 ppm; MS (ESI): m/z 375 [M + H]
+;A n a l .
calcd for C19H19ClN2O2S1 . 2H 2O: C, 57.55; H, 5.44; N,
7.07; S, 8.09. Found: C, 57.49; H, 5.34; N, 7.34; S, 8.19.
2-(3-Fluorophenyl)-3-(4-morpholinophenyl)thiazolidin-4-
one (8q)
Light yellow solid; m.p. 138°C; yield 95%. IR (CHCl3) ν:
1685 (C = O), 1609, 1593, 1516, 1488, 1450, 1379, 1333,
1305, 1263, 1234, 1177, 1143, 1121, 1072, 1052, 931,
902, 873, 826, 803, 754, 686, 665, 619 cm
-1;
1HN M R
(400 MHz, CDCl3) δ: 7.26-7.22 (m, 1 H, ArH), 7.07-6.89
(m, 5H, ArH), 6.79 (dd, J1 =6 . 8H z ,J2 = 2.2 Hz, 2 H,
ArH), 5.96 (d, J = 1.4 Hz, 1 H, CH), 3.98 (dd, J1 =1 5 . 7
Hz, J2 = 1.6 Hz, 1 H, CH2), 3.86 (dd, J1 =1 5 . 8H z ,J2 =
0 . 4H z ,1H ,C H 2), 3.80 (t, J = 4.8 Hz, 4 H, morpholine
H), 3.09 (t, J = 4.8 Hz, 4 H, morpholine H) ppm;
13C
NMR (100 MHz, CDCl3) δ: 170.83, 150.00, 130.36,
130.27, 128.71, 126.75, 122.64, 115.92, 115.64, 114.08,
113.85, 66.62, 65.00, 48.63, 33.12 ppm; MS (ESI): m/z
359 [M + H]
+; Anal. calcd for C19H19FN2O2S: C, 63.67;
H ,5 . 3 4 ;N ,7 . 8 2 ;S ,8 . 9 5 .F o u n d :C ,6 3 . 4 5 ;H ,5 . 4 5 ;N ,
7.47; S, 8.74.
3-(3-Morpholinopropyl)-2-(4-(trifluoromethyl)phenyl)
thiazolidin-4-one (11)
Brown gummy solid; yield 96%. IR (CHCl3) ν: 1681 (C =
O), 1619, 1447, 1410, 1325, 1273, 1209, 1165, 1117,
1067, 1017, 1034, 955, 917, 862, 813, 775, 750, 667 cm
-1;
1H NMR (400 MHz, CDCl3) δ:7 . 6 4( d ,J = 8.2 Hz, 2 H,
ArH), 7.41 (d, J = 8.0 Hz, 2 H, ArH), 5.70 (d, J = 1.8 Hz,
1 H, CH), 3.80 (dd, J1 = 15.4 Hz, J2 = 1.8 Hz, 1 H, CH2),
3.73-3.66 (m, 2 H), 3.64 (t, J = 4.5 Hz, 4 H, morpholine
H), 2.76-2.69 (m, 1 H, aliphatic CH2), 2.33 (t, J =4 . 5
Hz, 4 H, morpholine H), 2.29-2.20 (m, 2 H, aliphatic
CH2), 1.72-1.56 (m, 2 H, aliphatic CH2) ppm;
13CN M R
(100 MHz, CDCl3) δ: 171.19, 143.76, 127.23, 126.09,
126.05, 66.64, 62.86, 55.57, 53.34, 41.28, 32.68, 23.43
ppm; MS (ESI): m/z 375 [M + H]
+.
In vitro antibacterial assay
The antibacterial activities of all the prepared compounds
were evaluated against a Gram-positive bacterial strain
viz, Kp and Sa, and a Gram-positive bacteria, viz., Sa
aand three Gram-negative bacteria viz. Ec, Kp and Pa by
the NCCLS Method using Mueller Hinton broth in 96-
well tissue culture plates. The bacterial strains were
grown on nutrient agar at 37°C. After 24 h of incubation,
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ing Tween 20 at 0.05% concentration of approximately
1.0-2.0 × 10
7 cells/mL by matching with McFarland stan-
dards. Proper growth control, drug control, and the nega-
tive control were adjusted on to the plate. Compounds
were dissolved in dimethyl sulfoxide at a concentration
of 1 mg/mL, and 20 mL of this solution was added to
each well of 96-well tissue culture plate having 180 mL of
Mueller Hinton broth. The solution was then serially
diluted to afford twofold serial dilutions of the test com-
pounds in the subsequent wells. Then, McFarland-matched
bacterial suspension (100 mL) was diluted with 10 mL of
media. The diluted bacterial suspension (100 mL) was
added to each well and then kept for incubation. The maxi-
mum concentration of compounds tested was 50 mg/mL.
Microtitre plates were incubated at 35°C in a moist, dark
chamber. MICs were recorded spectrophotometrically after
24 h incubation. Gentamycin and ampicillin were used as
reference anti-bacterial agents.
In vitro antifungal assay
The in vitro antifungal activity of 4-thiazolidinone deriva-
tives (8a-q and 11) was investigated against six pathogenic
fungi, viz., Ca, Cn, Ss, Tm, Af, and Cp by broth microdilu-
tion technique as per guidelines of the National Commit-
tee for Clinical Laboratory Standards [17] using RPMI
Medium 1640 buffered with MOPS [3-(N-morpholino)
propanesulphonic acid] in microtitre plates. The starting
inoculums of test culture were 1-5 × 10
3 cfu/mL. Microti-
ter plates were incubated at 35°C. Minimal inhibitory con-
centrations were determined by spectrophotometric
method at 492 nm after 24-48 h (yeasts) and 72-96 h
(mycelial fungi) incubations. Ketoconazole and fluconazole
were used as reference fungicides.
Abbreviations
MIC: minimum inhibitory concentration; PEG: polyethylene glycol; PPG:
polypropylene glycol.
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